Mariner’s MaxCyte MXCT Stock Holding History

Mariner’s Portfolio MXCT Stock Details MXCT Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$119K	Buy	96,672 +53,059	+122%	+$52.9K	﹤0.01%	3300
2026 Q1	$30.6K	Buy	+43,613	New	+$40.7K	﹤0.01%	3468

Other funds holding MXCT

CFM

Capricorn Fund Managers London, United Kingdom $1.27B AUM 70.17% 1-Year Est. Return

Vitruvian Partners London, United Kingdom $201M AUM 10.44% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Mudita Advisors London, United Kingdom $481M AUM 73.74% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

BFM

Brooklands Fund Management London, United Kingdom $128M AUM

BNP Paribas Asset Management Paris, France $99.8B AUM 45.22% 1-Year Est. Return

CCM

Cadian Capital Management New York $1.32B AUM 4.19% 1-Year Est. Return

PLC

Peapod Lane Capital Bedford Hills, New York $148M AUM 89.92% 1-Year Est. Return

Mariner's MXCT Position: Q2 2026 in Review

Mariner increased its MaxCyte (MXCT) stake by 122% in Q2 2026, buying an estimated $52.9K and bringing the position to 96,672 shares worth $119K. The position accounts for ﹤0.01% of the portfolio, ranked #3300.

Mariner first reported a position in MXCT in Q1 2026 and has held it in 2 quarters since. 123 funds tracked by Wall St. Rank hold MXCT as of Q2 2026.

Mariner held 96,672 shares of MaxCyte worth $119K as of Q2 2026.
Mariner bought 53,059 MaxCyte shares in Q2 2026, an estimated $52.9K.
MaxCyte made up ﹤0.01% of Mariner's portfolio in Q2 2026, its #3300 holding.
Mariner first reported a position in MaxCyte in Q1 2026 and has held it in 2 quarters since.
123 funds tracked by Wall St. Rank held MaxCyte as of Q2 2026.

Based on Mariner's 13F filing for Q2 2026, filed 13 Aug 2026.